|
Inflammatory dermatosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We produced models of skin inflammation induced by imiquimod (IMQ) and IL-23 and tested the effect of inhibiting LAT1 (JPH203) and mammalian target of rapamycin (mTOR [rapamycin]).
|
31605740 |
2020 |
|
Inflammatory dermatosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data demonstrate that the IL-23 MC model is a useful approach to study IL-23/IL-17-driven skin inflammation and may facilitate preclinical assessment of novel therapies.
|
31062408 |
2019 |
|
Inflammatory dermatosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data point to an important contribution of Mon/Mac cells in IL-23 related skin inflammation and suggest that these cells are a significant player in the underlying pathophysiology of psoriasis.
|
30926837 |
2019 |
|
Inflammatory dermatosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To elucidate the possible role of IL-36 signalling in IL-23/Th17 pathway, the ability of anti-IL-36R mAbs to inhibit skin inflammation in an IL-23 ear injection model was assessed.
|
30417427 |
2019 |
|
Inflammatory dermatosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Conversely, reducing mtROS production or DC-specific deficiency in XBP1 attenuated IL-23 expression and skin inflammation in an IL-23-dependent model of psoriasis.
|
31031005 |
2019 |
|
Inflammatory dermatosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The goal of this manuscript is to provide a comprehensive disease and pharmacological assessment of IL-23 driven skin inflammation and its similarity to human psoriatic skin.
|
30149967 |
2018 |
|
Inflammatory dermatosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The tildrakizumab-induced reduction in skin inflammation proves the important pathogenic role of IL-23 in psoriasis and further supports the utility of drugs targeting the IL-23/Th17 pathway.
|
30081696 |
2018 |
|
Inflammatory dermatosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The antibody inhibited cutaneous inflammation in an IL-23-induced psoriatic-like skin inflammation model.
|
29474945 |
2018 |
|
Inflammatory dermatosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The vitamin D<sub>3</sub> analog, maxacalcitol, reduces psoriasiform skin inflammation by inducing regulatory T cells and downregulating IL-23 and IL-17 production.
|
30166055 |
2018 |
|
Inflammatory dermatosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we use a genetic mouse model to show that keratinocyte-produced IL-23 is sufficient to cause a chronic skin inflammation with an IL-17 profile.
|
29650963 |
2018 |
|
Inflammatory dermatosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
KC-Tie2 mice develop psoriasiform skin inflammation with increases in IL-23 and IL-17A and proinflammatory monocytosis and neutrophilia that precedes development of carotid artery thrombus formation.
|
28951241 |
2018 |
|
Inflammatory dermatosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression of the chemokine receptor Ccr6 is shared by most IL-22-producing cells, and Ccr6-deficient mice showed decreased IL-22 production and skin inflammation upon IL-23 intradermal injections.
|
28115058 |
2017 |
|
Inflammatory dermatosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that haplo-insufficient A20+/- mice develop severe toll-like receptor (TLR)-induced skin inflammation compared to wild type mice owing to amplified production of interleukin (IL)-17 and IL-23.
|
28658319 |
2017 |
|
Inflammatory dermatosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, in vivo, blocking or knockdown CCN1 expression ameliorated skin inflammation and reduced the expression of CCL20 in both imiquimod and IL-23-induced psoriasis-like mouse models, which indicated that CCN1 might be involved in the regulation of CCL20 production in psoriasis.
|
28602508 |
2017 |
|
Inflammatory dermatosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Administration of CCX2553 ameliorated skin inflammation in both the IL-23-induced ear swelling model and the topical imiquimod model, and significantly reduced the number of γδT17 cells in inflamed skin.
|
28972090 |
2017 |
|
Inflammatory dermatosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Psoriasis is a chronic immune-mediated inflammatory skin disease in which the alteration of the interleukin-23 (IL-23)/IL-17 cytokine axis appears to be crucial from a pathogenetic perspective.
|
28650001 |
2017 |
|
Inflammatory dermatosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treating KC-Tie2x<i>Mrp14</i><sup>-/-</sup> mice with anti-IL-23p19 antibodies reversed the skin inflammation, improved thrombosis, and decreased IL-6.
|
27942589 |
2016 |
|
Inflammatory dermatosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of the IL-23/Th17 pathway with monoclonal antibodies reduces skin inflammation in animal models.
|
25223230 |
2015 |
|
Inflammatory dermatosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together with the inhibition of IL-23-induced inflammation by treatment with neutralizing antibodies against IL-17 or IL-22, Tyk2 participates in both IL-23 and IL-22 signal transduction to mediate psoriasis-like skin inflammation.
|
24345760 |
2014 |
|
Inflammatory dermatosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The impact of γδ T cells, accounting for an important source of IL-17 in acute murine IL-23- and imiquimod-induced skin inflammation, in human psoriasis is still unclear.
|
24190659 |
2013 |
|
Inflammatory dermatosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To test this hypothesis, we determined whether the loss of EC-SOD causes more severe IL-23-induced skin inflammation.
|
23223134 |
2013 |
|
Inflammatory dermatosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis.
|
19380832 |
2009 |